Here's one:batshitcrazyweirdo wrote:
I'd sure like to see those 'papers and facts' you have, that's for sure.
Adverse effects of testosterone replacement therapy: an update on the evidence and controversy
Anthony Grech, John Breck, and Joel Heidelbaugh Ther Adv Drug Saf. 2014 Oct; 5(5): 190–200.
The available evidence indicates that TRT is largely considered to be safe in most men, with a small inherent risk of adverse events in selected high-risk populations of men with multiple medical comorbidities. TD is associated with an increased risk of development of cardiovascular and metabolic disease; however, the nature of the relationship remains unclear and recent evidence suggests that TRT may increase risk of adverse cardiovascular events in men with significant comorbidities. TRT has been associated with occasional modest increases in serum PSA, yet within safe clinical parameters, and without substantial compelling evidence to support an increased risk of prostate cancer. LUTS appear to remain stable or improve slightly with the use of TRT, which offers a differing viewpoint to previously held opinions. There remain little data on TRT relating to long-term OSA outcomes; however, current evidence suggests TRT may transiently worsen objective OSA parameters then resolve. TRT appears to be associated with erythrocytosis, yet data on the significance of this trend related to patient outcomes are lacking.
At this time, TRT remains a largely beneficial option in improving health-related quality of life in men with serum TD and associated symptoms. As of January 2014, the FDA stated they are investigating the potential link but have not concluded ‘FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death’. Clinicians should exercise caution when considering TRT for men with multiple cardiovascular comorbidities and utilize shared decision making with informed consent. As with any therapeutic intervention, clinicians should discuss the benefits and potential risks of hormone replacement therapy with men prior to initiating treatment, as well as discuss provisions for ongoing management and surveillance.
Complete paper here:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212439/